Iveta Kudaba
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Papers in
- Oncology 18
- Cancer Immunotherapy and Biomarkers 6
- Lung Cancer Research Studies 3
- HER2/EGFR in Cancer Research 3
-
- Lung Cancer Treatments and Mutations 3
- Gastric Cancer Management and Outcomes 3
- Co-authors
- Igor Bondarenko (4 shared papers)H.Z. Turna (2 shared papers)Dariusz Mirosław Kowalski (2 shared papers)Bogusława Karaszewska (2 shared papers)K.K. Laktionov (2 shared papers)Tony S.K. Mok (2 shared papers)Gilberto de Castro Junior (2 shared papers)Yi-Long Lung Cancer Wu (2 shared papers)
- Journals
- Annals of Oncology (8 papers)International Journal of Cancer (2 papers)The Lancet (2 papers)The Lancet Oncology (1 paper)Journal of Clinical Oncology (1 paper)
- Partner nations
- LatviaUnited StatesJapan
In The Last Decade
Iveta Kudaba
21 papers receiving 7.1k citations
Iveta Kudaba's Hit Papers
Peers
Comparison fields: 5 of 97
- Otorhinolaryngology 864
- Oncology 4.2k
- Pulmonary and Respiratory Medicine 2.1k
- Cancer Research 570
- Immunology 797
Countries citing papers authored by Iveta Kudaba
This map shows the geographic impact of Iveta Kudaba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iveta Kudaba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iveta Kudaba more than expected).
Fields of papers citing papers by Iveta Kudaba
This network shows the impact of papers produced by Iveta Kudaba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iveta Kudaba. The network helps show where Iveta Kudaba may publish in the future.
Co-authors
The 25 scholars most cited alongside Iveta Kudaba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2019 | 2691 |
| 2 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2460 |
| 3 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Hit paper breakdown → | 2020 | 872 |
| 4 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 668 |
| 5 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study Hit paper breakdown → | 2022 | 222 |
| 6 | 2022 | 76 | |
| 7 | 2020 | 68 | |
| 8 | 2019 | 35 | |
| 9 | 2019 | 27 | |
| 10 | 2018 | 21 | |
| 11 | 2005 | 20 | |
| 12 | 2013 | 20 | |
| 13 | 2019 | 19 | |
| 14 | 2021 | 15 | |
| 15 | 2020 | 12 | |
| 16 | 2019 | 6 | |
| 17 | 2019 | 3 | |
| 18 | 2012 | 2 | |
| 19 | 1996 | 1 | |
| 20 | 2011 | 1 |
About Iveta Kudaba
Iveta Kudaba is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Epidemiology and Otorhinolaryngology, having authored 22 papers that have together received 7.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (3 papers), Neuroendocrine Tumor Research Advances (3 papers), Lung Cancer Research Studies (3 papers), Lung Cancer Treatments and Mutations (3 papers), Gastric Cancer Management and Outcomes (3 papers), Cancer therapeutics and mechanisms (3 papers) and HER2/EGFR in Cancer Research (3 papers). The work is most often cited by research in Otorhinolaryngology (864 citations), Oncology (4.2k citations), Pulmonary and Respiratory Medicine (2.1k citations), Cancer Research (570 citations) and Immunology (797 citations). Iveta Kudaba has collaborated with scholars based in Latvia, United States and Japan. Frequent co-authors include Igor Bondarenko, H.Z. Turna, Dariusz Mirosław Kowalski, Bogusława Karaszewska, K.K. Laktionov, Tony S.K. Mok, Gilberto de Castro Junior, Yi-Long Lung Cancer Wu, Vichien Srimuninnimit and Byoung Chul Cho. Their work appears in journals such as Annals of Oncology, International Journal of Cancer, The Lancet, The Lancet Oncology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.